261 related articles for article (PubMed ID: 36276148)
1. Anti-cancer immune responses to DNA damage response inhibitors: Molecular mechanisms and progress toward clinical translation.
Carlsen L; El-Deiry WS
Front Oncol; 2022; 12():998388. PubMed ID: 36276148
[TBL] [Abstract][Full Text] [Related]
2. Targeting DNA damage response pathways to activate the STING innate immune signaling pathway in human cancer cells.
Wayne J; Brooks T; Landras A; Massey AJ
FEBS J; 2021 Aug; 288(15):4507-4540. PubMed ID: 33529438
[TBL] [Abstract][Full Text] [Related]
3. Triple kill: DDR inhibitors, radiotherapy and immunotherapy leave cancer cells with no escape.
Qiu Y; Hu X; Zeng X; Wang H
Acta Biochim Biophys Sin (Shanghai); 2022 Oct; 54(11):1569-1576. PubMed ID: 36305726
[TBL] [Abstract][Full Text] [Related]
4. The DNA Damaging Revolution: PARP Inhibitors and Beyond.
Yap TA; Plummer R; Azad NS; Helleday T
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():185-195. PubMed ID: 31099635
[TBL] [Abstract][Full Text] [Related]
5. Enhancing anti-tumour innate immunity by targeting the DNA damage response and pattern recognition receptors in combination with radiotherapy.
Chan Wah Hak CML; Rullan A; Patin EC; Pedersen M; Melcher AA; Harrington KJ
Front Oncol; 2022; 12():971959. PubMed ID: 36106115
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in DDR (DNA damage response) inhibitors for cancer therapy.
Cheng B; Pan W; Xing Y; Xiao Y; Chen J; Xu Z
Eur J Med Chem; 2022 Feb; 230():114109. PubMed ID: 35051747
[TBL] [Abstract][Full Text] [Related]
7. Predictive and Prognostic Value of DNA Damage Response Associated Kinases in Solid Tumors.
Gachechiladze M; Skarda J; Bouchalova K; Soltermann A; Joerger M
Front Oncol; 2020; 10():581217. PubMed ID: 33224881
[TBL] [Abstract][Full Text] [Related]
8. Targeting DNA Damage Repair and Immune Checkpoint Proteins for Optimizing the Treatment of Endometrial Cancer.
Bian X; Sun C; Cheng J; Hong B
Pharmaceutics; 2023 Aug; 15(9):. PubMed ID: 37765210
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.
Massey AJ
Cancer Lett; 2016 Dec; 383(1):41-52. PubMed ID: 27693461
[TBL] [Abstract][Full Text] [Related]
10. Could Inhibiting the DNA Damage Repair Checkpoint Rescue Immune-Checkpoint-Inhibitor-Resistant Endometrial Cancer?
Li Y; Wang X; Hou X; Ma X
J Clin Med; 2023 Apr; 12(8):. PubMed ID: 37109350
[TBL] [Abstract][Full Text] [Related]
11. Anti-Tumor Effect of Inhibition of DNA Damage Response Proteins, ATM and ATR, in Endometrial Cancer Cells.
Takeuchi M; Tanikawa M; Nagasaka K; Oda K; Kawata Y; Oki S; Agapiti C; Sone K; Miyagawa Y; Hiraike H; Wada-Hiraike O; Kuramoto H; Ayabe T; Osuga Y; Fujii T
Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31805725
[No Abstract] [Full Text] [Related]
12. Everything Comes with a Price: The Toxicity Profile of DNA-Damage Response Targeting Agents.
Martorana F; Da Silva LA; Sessa C; Colombo I
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205700
[TBL] [Abstract][Full Text] [Related]
13. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.
Sen T; Rodriguez BL; Chen L; Corte CMD; Morikawa N; Fujimoto J; Cristea S; Nguyen T; Diao L; Li L; Fan Y; Yang Y; Wang J; Glisson BS; Wistuba II; Sage J; Heymach JV; Gibbons DL; Byers LA
Cancer Discov; 2019 May; 9(5):646-661. PubMed ID: 30777870
[TBL] [Abstract][Full Text] [Related]
14. Targeting DNA repair pathway in cancer: Mechanisms and clinical application.
Wang M; Chen S; Ao D
MedComm (2020); 2021 Dec; 2(4):654-691. PubMed ID: 34977872
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Targeting of DNA Damage Response in Cancer.
Choi W; Lee ES
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163621
[TBL] [Abstract][Full Text] [Related]
16. Targeting DNA damage response components induces enhanced STING-dependent type-I IFN response in ATM deficient cancer cells and drives dendritic cell activation.
Lopez-Pelaez M; Young L; Vazquez-Chantada M; Nelson N; Durant S; Wilkinson RW; Poon E; Gaspar M; Valge-Archer V; Smith P; Dovedi SJ
Oncoimmunology; 2022; 11(1):2117321. PubMed ID: 36117525
[TBL] [Abstract][Full Text] [Related]
17. Clinical translation for targeting DNA damage repair in non-small cell lung cancer: a review.
Mao X; Lee NK; Saad SE; Fong IL
Transl Lung Cancer Res; 2024 Feb; 13(2):375-397. PubMed ID: 38496700
[TBL] [Abstract][Full Text] [Related]
18. Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control.
Concannon K; Morris BB; Gay CM; Byers LA
Mol Cell; 2023 Mar; 83(5):660-680. PubMed ID: 36669489
[TBL] [Abstract][Full Text] [Related]
19. Targeting the DNA damage response for patients with lymphoma: Preclinical and clinical evidences.
Carrassa L; Colombo I; Damia G; Bertoni F
Cancer Treat Rev; 2020 Nov; 90():102090. PubMed ID: 32892059
[TBL] [Abstract][Full Text] [Related]
20. Targeting MUS81 promotes the anticancer effect of WEE1 inhibitor and immune checkpoint blocking combination therapy via activating cGAS/STING signaling in gastric cancer cells.
Li C; Shen Q; Zhang P; Wang T; Liu W; Li R; Ma X; Zeng X; Yin Y; Tao K
J Exp Clin Cancer Res; 2021 Oct; 40(1):315. PubMed ID: 34625086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
